Table 1.
Demographic, clinicopathological and treatment characteristics of study population
| Characteristic | N (%) |
|---|---|
|
| |
| No. of patients | 539 |
| Age in years: median (range) | 64 (39–83) |
| < 65 years | 271 (50.3) |
| ≥ 65 years | 268 (49.7) |
| Gender | |
| Male | 315 (58.4) |
| Female | 224 (41.6) |
| Smoking status (n = 537; completeness = 99.6 %) | |
| Current | 257 (47.8) |
| Former | 212 (39.5) |
| Never | 68 (12.7) |
| Histology | |
| Adenocarcinoma | 341 (63.3) |
| Squamous-cell carcinoma | 195 (36.2) |
| NSCLC other rare types | 3 (0.6) |
| EGFRa status in non-squamous NSCLC | |
| (n = 334; completeness = 99.7%) | |
| Positive | 41 (12.3) |
| Negative | 292 (87.7) |
| ALKb status in non-squamous NSCLC | |
| (n = 334; completeness = 39.2%) | |
| Positive | 7 (5.3) |
| Negative | 124 (94.7) |
| Clinical TNM stage c | |
| I | 309 (57.3) |
| II | 145 (26.9) |
| IIIA | 85 (15.8) |
| Clinical T stage | |
| T1 | 242 (44.9) |
| T2 | 193 (35.8) |
| T3 | 96 (17.8) |
| T4 | 8 (1.5) |
| Clinical N stage | |
| N0 | 393 (72.9) |
| N1 | 102 (18.9) |
| N2 | 44 (8.2) |
| Pathological TNM stagec (n = 532; completeness = 98.7%) | |
| I | 296 (55.6) |
| II | 150 (28.2) |
| III | 86 (16.2) |
| Pathological T stage (n = 537; completeness = 99.6%) | |
| T1 | 223 (41.5) |
| T2 | 248 (46.2) |
| T3 | 58 (10.8) |
| T4 | 8 (1.5) |
| Pathological N stage (n = 534; completeness = 99.1% | |
| N0 | 386 (72.3) |
| N1 | 81 (15.2) |
| N2 | 67 (12.5) |
| Surgery type | |
| Lobectomy | 459 (85.2) |
| Bilobectomy | 31 (5.8) |
| Pneumonectomy | 49 (9.1) |
| Adjuvant treatment | |
| Platinum-based chemotherapy | 146 (27.1) |
| Postoperative radiotherapy | 36 (6.7) |
a
EGFR: epidermal growth factor receptor; bALK: anaplastic lymphoma kinase; cstage defined by American Joint Committee on Cancer staging